Clinical trial · Interventional
A Prospective, Open-label, Single-arm Clinical Study
A Prospective, Open-label, Single-arm Clinical Study Evaluating Tumor Treating Fields (TTFields) in Combination With Chemotherapy for Recurrent Glioblastom
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the study is a prospective, single-arm, open-label trial, designed to explore the efficacy and safety of Tumor-Treating Fields (TTFields) combined with second-line chemotherapy treatment in recurrent glioblastoma multiforme (GBM) , TTFields is an portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TTFields | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Second line conventional treatment
- interventionNames
- Combination Product: TTFields
Primary outcomes (1)
- measure
- OS6
- timeFrame
- 6 months
- description
- Overall survival at 6 months
Secondary outcomes (4)
- measure
- Overall survival at 12 months (OS12)
- timeFrame
- 12 months
- description
- To evaluate the OS12 of patients with recurrent glioblastoma treated with TTFields combined with chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Sign written informed consent prior to any procedure related to the study; 2. Recurrence and pathologically confirmed WHO Grade IV glioblastoma (GBM); 3. The tumor is located in the supratentorial area 4. Age ≥18 years; 5. Received radiotherapy and maintenance treatment with temozolomide; 6. Expected survival time: \> 3 months; 7. KPS score ≥60; 8. Ability to comply with the plan; Exclusion Criteria: 1. Other clinical trials are being tried 2. Had major surgery within 4 weeks before the start of the study or had not recovered after the surgery 3. Received radiotherapy within 4 weeks before the study 4. Received chemotherapy within 4 weeks before the study 5. Women during pregnancy; 6. Allergic to hydrogels; 7. There are important implants in the body, such as pacemaker, defibrillator, shunt tube, deep brain stimulator, etc.; 8. Patients with significantly increased intracranial pressure (shifted \>5mm in imaging midline, obvious papilloma, nausea, vomiting, and decreased consciousness)
References
Publications (0)
Data not yet available